Iovance Biotherapeutics

CGTs disrupt treatment for genetic diseases, with 69 marketed worldwide and 7 novel FDA approvals in 2023. Oncology leads CGTs, projected to reach $37bn by 2030. Outsourcing vs. in-house manufacturing is crucial, with Lonza Group as the leading CMO for marketed CGTs.

The article discusses the importance of SSR (Server-Side Rendering) in web development for improving performance and user experience.

Aethlon Medical's Hemopurifier® aims to enhance anti-PD-1 therapy by removing tumor-produced extracellular vesicles, with ethics approval for a clinical trial in India following approvals in Australia. The trial will evaluate Hemopurifier® in solid tumor patients with stable or progressive disease during anti-PD-1 monotherapy, with other companies like Immuneering and Iovance Biotherapeutics also advancing immunotherapy treatments.

Aethlon Medical's Hemopurifier®, an immunotherapeutic device for cancer, gains ethics approval in India for a trial in solid tumor patients resistant to anti-PD-1 therapy. The trial aims to assess safety and feasibility, with potential to improve response rates to anti-PD-1 antibodies by removing tumor-produced extracellular vesicles.

The Global TIL Therapy Market is projected to grow from USD 0.092 Billion in 2024 to USD 9.20 Billion by 2031, driven by personalized immunotherapy advancements, increasing cancer research investments, and successful clinical trials. Key players include Iovance Biotherapeutics, Instil Bio, Obsidian Therapeutics, Cellectis, and Cellular Biomedicine Group.

DelveInsight's 'Non-Small-Cell Lung Cancer Pipeline Insight 2024' covers 135+ companies and 150+ pipeline drugs, highlighting key players like BridgeBio Pharma, Daiichi Sankyo, and Merck. Prominent therapies include Trastuzumab deruxtecan, DS-1062a, and Pembrolizumab. Recent studies by Merck, AstraZeneca, and Gilead focus on Phase 3 trials for V940, Durvalumab, and Zimberelimab, respectively.

Geron Corporation appoints Jim Ziegler as Executive VP, Chief Commercial Officer to lead global commercial strategy and drive growth of RYTELO™, effective September 9, 2024.

Iovance Biotherapeutics' MDA-TIL trial terminated due to lack of efficacy, leading to drops in Phase Transition Success Rates (PTSR) in various cancers. Sention Therapeutics' ST-1891 and Armata Pharmaceuticals' APPA-02 trials completed successfully in hypothyroidism and bronchiectasis, respectively, boosting their PTSRs. Karyopharm Therapeutics' Xpovio trial in metastatic melanoma and Worg Pharmaceuticals Hangzhou's WP-1302 trial in Graves' disease were terminated, affecting their PTSRs negatively.